ArticleHereditas2026
Serum LINC01127 serves as a diagnostic biomarker for sepsis and its predictive value for clinical outcomes.
Article in Hereditas, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aims to investigate the role of LINC01127 in sepsis and evaluate its potential clinical value.
methodsThis study included 102 sepsis patients and 102 controls matched for age and gender. Serum levels of LINC01127 and miR-34b-5p were measured using quantitative real-time PCR (RT-qPCR). Receiver operating characteristic (ROC) curves were constructed to assess the diagnostic efficacy of LINC01127 for sepsis, while Kaplan-Meier curves evaluated its prognostic significance during 28-day follow-up. Lipopolysaccharide (LPS)-induced THP-1 cells were used to simulate an in vitro sepsis model. Enzyme-linked immunosorbent assay (ELISA) measured proinflammatory factor levels, and flow cytometry assessed apoptosis.
resultsSerum LINC01127 exhibited downregulation in sepsis-affected individuals, while miR-34b-5p was upregulated. ROC curve analysis demonstrated that LINC01127 possesses good diagnostic value for sepsis. Kaplan-Meier analysis showed that low LINC01127 levels were associated with poorer prognosis during the 28-day follow-up. Bioinformatics analysis successfully predicted a binding site for miR-34b-5p on LINC01127, and dual-luciferase reporter (DLR) and RNA immunoprecipitation (RIP) assays confirmed their target relationship. Cell experiments demonstrated that upregulating LINC01127 significantly reduced the apoptosis and inflammation triggered by LPS, while increasing miR-34b-5p expression markedly reversed these effects.
conclusionLINC01127 may serve as a promising biomarker for sepsis, alleviating apoptosis and inflammatory responses through targeting miR-34b-5p. This offers novel insights into sepsis diagnosis and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.